13F Holdings
中文EN

ABUS Arbutus Biopharma Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 1447028 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,142.6%
TTM net income YoY620.2%
TTM EPS YoY587.0%
Revenue 3-yr CAGR101.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin81.1%
Net margin121.2%
FCF margin—
EBITDA margin81.1%

Returns

ROE269.6%
ROA100.6%
ROIC (approx.)—
Asset turnover0.83x

Leverage & solvency

Liabilities / assets74.8%
Debt / equity0.00x
Current ratio1.40x
Interest coverage2,299.38x

Cash quality & payout

Operating cash flow / net income1.00x
Accruals ratio-0.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$14.08M$6.17M$18.14M$39.02M$10.99M
R&D expense$25.24M$54.04M$73.70M$84.41M$65.50M
SG&A expense$15.89M$22.11M$22.48M$17.83M$17.14M
Operating income-$38.16M-$76.32M-$78.10M-$65.46M-$73.52M
Interest expense$97,000$137,000$459,000$1.73M$2.86M
Pretax income$11.95M-$1.67M-$14.80M-$28.70M-$7.70M
Income tax$0$0$0$4.44M$0
Net income-$33.50M-$69.92M-$72.85M-$69.46M-$76.25M
EBITDA-$37.80M-$74.94M-$76.70M-$64.03M-$71.77M
EPS (basic)-0.17-0.38-0.44-0.46-0.83
EPS (diluted)-0.17-0.38-0.44-0.46-0.83
Weighted avg. shares (diluted)191.60M185.61M165.96M150.94M106.24M
Balance sheet
Cash & equivalents$18.01M$36.33M$26.29M$30.78M$109.28M
Short-term investments$73.46M$86.29M$99.72M$116.14M$46.03M
Receivables$1.45M$2.41M$1.78M$1.35M$899,000
Current assets$94.46M$127.32M$132.03M$151.14M$160.66M
PP&E, net$32,000$3.31M$4.67M$5.07M$5.98M
Total assets$94.62M$131.71M$144.40M$195.42M$204.49M
Current liabilities$6.01M$15.62M$22.49M$32.86M$11.22M
Long-term debt$0$0$0$0$0
Total debt$0$0$0$0$0
Total liabilities$18.04M$34.34M$38.38M$58.57M$35.05M
Shareholders' equity$76.58M$97.37M$106.02M$136.85M$169.44M
Net debt-$18.01M-$36.33M-$26.29M-$30.78M-$109.28M
Shares outstanding192.53M189.96M169.87M157.46M144.99M
Cash flow statement
Operating cash flow-$39.64M-$64.85M-$85.94M-$35.36M-$67.53M
Capital expenditure$0$182,000$1.01M$512,000$809,000
Free cash flow-$39.64M-$65.03M-$86.94M-$35.87M-$68.34M
Investing cash flow$15.58M$22.95M$50.77M-$74.94M-$12.68M
Financing cash flow$5.72M$52.00M$30.65M$31.81M$137.24M
Depreciation & amortization$363,000$1.38M$1.40M$1.43M$1.75M
Stock-based compensation$6.95M$8.99M$9.30M$7.18M$6.42M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.